MovDisordV3, PascalFrancis, Corpus, bibRecord, 002366

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Identifieur interne : 002366 ( PascalFrancis/Corpus ); précédent : 002365; suivant : 002367

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Auteurs : Yoshikuni Mizuno ; Nobuo Yanagisawa ; Sadako Kuno ; Mitsutoshi Yamamoto ; Kazuko Hasegawa ; Hideki Origasa ; Hisayuki Kowa

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:04-0095349

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Stade avancé, Pramipexole, Chimiothérapie, Lévodopa, Bromocriptine, Randomisation, Etude double insu, Etude multicentrique, Traitement adjuvant, Etude comparative, Pronostic, Adulte.

English descriptors

KwdEn :
- Adjuvant treatment, Adult, Advanced stage, Bromocriptine, Chemotherapy, Comparative study, Double blind study, Levodopa, Multicenter study, Parkinson disease, Pramipexole, Prognosis, Randomization.

Abstract

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease`
A11	`01`	`1`		`@1 MIZUNO (Yoshikuni)`
A11	`02`	`1`		`@1 YANAGISAWA (Nobuo)`
A11	`03`	`1`		`@1 KUNO (Sadako)`
A11	`04`	`1`		`@1 YAMAMOTO (Mitsutoshi)`
A11	`05`	`1`		`@1 HASEGAWA (Kazuko)`
A11	`06`	`1`		`@1 ORIGASA (Hideki)`
A11	`07`	`1`		`@1 KOWA (Hisayuki)`
A14	`01`			`@1 Department of Neurology, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 1 aut.`
A14	`02`			`@1 Kanto Rosai Hospital @2 Kawasaki @3 JPN @Z 2 aut.`
A14	`03`			`@1 Center for Neurological disease, Clinical Research Section, Utano National Hospital @2 Kyoto @3 JPN @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Kagawa Prefectural Central Hospital @2 Takamatsu @3 JPN @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, Sagamihara National Hospital @2 Sagamihara @3 JPN @Z 5 aut.`
A14	`06`			`@1 Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University @2 Toyama @3 JPN @Z 6 aut.`
A14	`07`			`@1 Kitasato University @2 Tokyo @3 JPN @Z 7 aut.`
A17	`01`	`1`		`@1 The Japan Pramipexole Study Group @3 JPN`
A20				`@1 1149-1156`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000113383090080`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 04-0095349`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Stade avancé @5 02`
C03	`02`	`X`	`ENG`	`@0 Advanced stage @5 02`
C03	`02`	`X`	`SPA`	`@0 Estadio avanzado @5 02`
C03	`03`	`X`	`FRE`	`@0 Pramipexole @2 NK @2 FR @5 04`
C03	`03`	`X`	`ENG`	`@0 Pramipexole @2 NK @2 FR @5 04`
C03	`03`	`X`	`SPA`	`@0 Pramipexol @2 NK @2 FR @5 04`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`05`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 06`
C03	`05`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 06`
C03	`05`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 06`
C03	`06`	`X`	`FRE`	`@0 Bromocriptine @2 NK @2 FR @5 07`
C03	`06`	`X`	`ENG`	`@0 Bromocriptine @2 NK @2 FR @5 07`
C03	`06`	`X`	`SPA`	`@0 Bromocriptina @2 NK @2 FR @5 07`
C03	`07`	`X`	`FRE`	`@0 Randomisation @5 10`
C03	`07`	`X`	`ENG`	`@0 Randomization @5 10`
C03	`07`	`X`	`SPA`	`@0 Aleatorización @5 10`
C03	`08`	`X`	`FRE`	`@0 Etude double insu @5 11`
C03	`08`	`X`	`ENG`	`@0 Double blind study @5 11`
C03	`08`	`X`	`SPA`	`@0 Estudio doble ciego @5 11`
C03	`09`	`X`	`FRE`	`@0 Etude multicentrique @5 12`
C03	`09`	`X`	`ENG`	`@0 Multicenter study @5 12`
C03	`09`	`X`	`SPA`	`@0 Estudio multicéntrico @5 12`
C03	`10`	`X`	`FRE`	`@0 Traitement adjuvant @5 17`
C03	`10`	`X`	`ENG`	`@0 Adjuvant treatment @5 17`
C03	`10`	`X`	`SPA`	`@0 Tratamiento adyuvante @5 17`
C03	`11`	`X`	`FRE`	`@0 Etude comparative @5 18`
C03	`11`	`X`	`ENG`	`@0 Comparative study @5 18`
C03	`11`	`X`	`SPA`	`@0 Estudio comparativo @5 18`
C03	`12`	`X`	`FRE`	`@0 Pronostic @5 19`
C03	`12`	`X`	`ENG`	`@0 Prognosis @5 19`
C03	`12`	`X`	`SPA`	`@0 Pronóstico @5 19`
C03	`13`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`13`	`X`	`ENG`	`@0 Adult @5 20`
C03	`13`	`X`	`SPA`	`@0 Adulto @5 20`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Agoniste @5 45`
C07	`07`	`X`	`ENG`	`@0 Agonist @5 45`
C07	`07`	`X`	`SPA`	`@0 Agonista @5 45`
C07	`08`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 46`
C07	`08`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 46 @6 «D2» Dopamine receptor`
C07	`08`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 46`
C07	`09`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 47`
C07	`09`	`X`	`ENG`	`@0 Dopamine agonist @5 47`
C07	`09`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 47`
C07	`10`	`X`	`FRE`	`@0 Antiparkinsonien @5 48`
C07	`10`	`X`	`ENG`	`@0 Antiparkinson agent @5 48`
C07	`10`	`X`	`SPA`	`@0 Antiparkinsoniano @5 48`
C07	`11`	`X`	`FRE`	`@0 Neuroprotecteur @5 49`
C07	`11`	`X`	`ENG`	`@0 Neuroprotective agent @5 49`
C07	`11`	`X`	`SPA`	`@0 Neuroprotector @5 49`
C07	`12`	`X`	`FRE`	`@0 Ergot dérivé @5 53`
C07	`12`	`X`	`ENG`	`@0 Ergot derivatives @5 53`
C07	`12`	`X`	`SPA`	`@0 Ergot derivado @5 53`
N21				`@1 061`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 04-0095349 INIST
ET :	Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
AU :	MIZUNO (Yoshikuni); YANAGISAWA (Nobuo); KUNO (Sadako); YAMAMOTO (Mitsutoshi); HASEGAWA (Kazuko); ORIGASA (Hideki); KOWA (Hisayuki)
AF :	Department of Neurology, Juntendo University School of Medicine/Tokyo/Japon (1 aut.); Kanto Rosai Hospital/Kawasaki/Japon (2 aut.); Center for Neurological disease, Clinical Research Section, Utano National Hospital/Kyoto/Japon (3 aut.); Department of Neurology, Kagawa Prefectural Central Hospital/Takamatsu/Japon (4 aut.); Department of Neurology, Sagamihara National Hospital/Sagamihara/Japon (5 aut.); Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University/Toyama/Japon (6 aut.); Kitasato University/Tokyo/Japon (7 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 10; Pp. 1149-1156; Bibl. 25 ref.
LA :	Anglais
EA :	We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.
CC :	002B02B06
FD :	Parkinson maladie; Stade avancé; Pramipexole; Chimiothérapie; Lévodopa; Bromocriptine; Randomisation; Etude double insu; Etude multicentrique; Traitement adjuvant; Etude comparative; Pronostic; Adulte
FG :	Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Agoniste; Récepteur dopaminergique D2; Stimulant dopaminergique; Antiparkinsonien; Neuroprotecteur; Ergot dérivé
ED :	Parkinson disease; Advanced stage; Pramipexole; Chemotherapy; Levodopa; Bromocriptine; Randomization; Double blind study; Multicenter study; Adjuvant treatment; Comparative study; Prognosis; Adult
EG :	Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Agonist; D2 Dopamine receptor; Dopamine agonist; Antiparkinson agent; Neuroprotective agent; Ergot derivatives
SD :	Parkinson enfermedad; Estadio avanzado; Pramipexol; Quimioterapia; Levodopa; Bromocriptina; Aleatorización; Estudio doble ciego; Estudio multicéntrico; Tratamiento adyuvante; Estudio comparativo; Pronóstico; Adulto
LO :	INIST-20953.354000113383090080
ID :	04-0095349

Links to Exploration step

Pascal:04-0095349

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yanagisawa, Nobuo" sort="Yanagisawa, Nobuo" uniqKey="Yanagisawa N" first="Nobuo" last="Yanagisawa">Nobuo Yanagisawa</name>
<affiliation><inist:fA14 i1="02"><s1>Kanto Rosai Hospital</s1>
<s2>Kawasaki</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation><inist:fA14 i1="03"><s1>Center for Neurological disease, Clinical Research Section, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Origasa, Hideki" sort="Origasa, Hideki" uniqKey="Origasa H" first="Hideki" last="Origasa">Hideki Origasa</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University</s1>
<s2>Toyama</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kowa, Hisayuki" sort="Kowa, Hisayuki" uniqKey="Kowa H" first="Hisayuki" last="Kowa">Hisayuki Kowa</name>
<affiliation><inist:fA14 i1="07"><s1>Kitasato University</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0095349</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0095349 INIST</idno>
<idno type="RBID">Pascal:04-0095349</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002366</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yanagisawa, Nobuo" sort="Yanagisawa, Nobuo" uniqKey="Yanagisawa N" first="Nobuo" last="Yanagisawa">Nobuo Yanagisawa</name>
<affiliation><inist:fA14 i1="02"><s1>Kanto Rosai Hospital</s1>
<s2>Kawasaki</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation><inist:fA14 i1="03"><s1>Center for Neurological disease, Clinical Research Section, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Origasa, Hideki" sort="Origasa, Hideki" uniqKey="Origasa H" first="Hideki" last="Origasa">Hideki Origasa</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University</s1>
<s2>Toyama</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kowa, Hisayuki" sort="Kowa, Hisayuki" uniqKey="Kowa H" first="Hisayuki" last="Kowa">Hisayuki Kowa</name>
<affiliation><inist:fA14 i1="07"><s1>Kitasato University</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Adult</term>
<term>Advanced stage</term>
<term>Bromocriptine</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Double blind study</term>
<term>Levodopa</term>
<term>Multicenter study</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Prognosis</term>
<term>Randomization</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Stade avancé</term>
<term>Pramipexole</term>
<term>Chimiothérapie</term>
<term>Lévodopa</term>
<term>Bromocriptine</term>
<term>Randomisation</term>
<term>Etude double insu</term>
<term>Etude multicentrique</term>
<term>Traitement adjuvant</term>
<term>Etude comparative</term>
<term>Pronostic</term>
<term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MIZUNO (Yoshikuni)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YANAGISAWA (Nobuo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KUNO (Sadako)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YAMAMOTO (Mitsutoshi)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HASEGAWA (Kazuko)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ORIGASA (Hideki)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KOWA (Hisayuki)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Kanto Rosai Hospital</s1>
<s2>Kawasaki</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Center for Neurological disease, Clinical Research Section, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University</s1>
<s2>Toyama</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Kitasato University</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>The Japan Pramipexole Study Group</s1>
<s3>JPN</s3>
</fA17>
<fA20><s1>1149-1156</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113383090080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0095349</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Pramipexol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Randomization</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement adjuvant</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adjuvant treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento adyuvante</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Agonist</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Agonista</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>46</s5>
<s6>«D2» Dopamine receptor</s6>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>49</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>49</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>49</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>53</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>53</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>53</s5>
</fC07>
<fN21><s1>061</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0095349 INIST</NO>
<ET>Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</ET>
<AU>MIZUNO (Yoshikuni); YANAGISAWA (Nobuo); KUNO (Sadako); YAMAMOTO (Mitsutoshi); HASEGAWA (Kazuko); ORIGASA (Hideki); KOWA (Hisayuki)</AU>
<AF>Department of Neurology, Juntendo University School of Medicine/Tokyo/Japon (1 aut.); Kanto Rosai Hospital/Kawasaki/Japon (2 aut.); Center for Neurological disease, Clinical Research Section, Utano National Hospital/Kyoto/Japon (3 aut.); Department of Neurology, Kagawa Prefectural Central Hospital/Takamatsu/Japon (4 aut.); Department of Neurology, Sagamihara National Hospital/Sagamihara/Japon (5 aut.); Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University/Toyama/Japon (6 aut.); Kitasato University/Tokyo/Japon (7 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 10; Pp. 1149-1156; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.</EA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Stade avancé; Pramipexole; Chimiothérapie; Lévodopa; Bromocriptine; Randomisation; Etude double insu; Etude multicentrique; Traitement adjuvant; Etude comparative; Pronostic; Adulte</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Agoniste; Récepteur dopaminergique D2; Stimulant dopaminergique; Antiparkinsonien; Neuroprotecteur; Ergot dérivé</FG>
<ED>Parkinson disease; Advanced stage; Pramipexole; Chemotherapy; Levodopa; Bromocriptine; Randomization; Double blind study; Multicenter study; Adjuvant treatment; Comparative study; Prognosis; Adult</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Agonist; D2 Dopamine receptor; Dopamine agonist; Antiparkinson agent; Neuroprotective agent; Ergot derivatives</EG>
<SD>Parkinson enfermedad; Estadio avanzado; Pramipexol; Quimioterapia; Levodopa; Bromocriptina; Aleatorización; Estudio doble ciego; Estudio multicéntrico; Tratamiento adyuvante; Estudio comparativo; Pronóstico; Adulto</SD>
<LO>INIST-20953.354000113383090080</LO>
<ID>04-0095349</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002366 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002366 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0095349
   |texte=   Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri